News

Targeting FDA OK for its test against deadly sepsis, South Bay company raises $57 million

Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up

Inflammatix sepsis test scores FDA breakthrough device designation

Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test

Your medical devices are getting smarter. Can the FDA keep them safe?

Point-of-care testing for infectious diseases in emergency settings

Do Your Genes Know What’s Making You Sick?

Artificial Intelligence for Clinical Decision Support in Sepsis

Inflammatix Checks off All the Right Boxes with Investors

Inflammatix nets $102M to advance its immune system tests for infectious diseases

Infection-detection system from Peninsula company scores $102M, aims to hit market this year

A Bright Future Ahead for Novel Markers of Infection